Core Insights - Baron Health Care Fund reported a 5.39% increase in its Institutional Shares for Q3 2025, slightly outperforming the Russell 3000 Health Care Index which gained 5.05% but underperforming the broader Russell 3000 Index which rose by 8.18% [1] - The fund's performance was impacted by stock selection and negative effects from active sub-industry allocations and cash holdings during a rising market [1] Company Highlights - Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a biotechnology company focused on developing a long-acting antiviral drug for flu prevention, which is not a vaccine but aims to provide a single-dose universal preventative against all flu strains [3] - Cidara's antiviral drug demonstrated up to 76% protection from symptomatic influenza over 24 weeks in a Phase 2b clinical trial, significantly outperforming traditional flu vaccines which average about 40% efficacy [3] - The company is currently enrolling participants for a Phase 3 trial targeting adults over 65 and those aged 12 and older with high-risk co-morbidities or immune compromise [3] - Cidara Therapeutics has a market capitalization of $2.605 billion, with its stock closing at $102.73 per share on November 3, 2025, and has seen a remarkable 674.74% increase in value over the past 52 weeks [2][3]